Driving tomorrow’s therapies
through relentless innovation
By expanding the pipeline through continuous R&D, we will become a hub for next-generation therapeutics development.
through relentless innovation
Central Research Institute

| Category | Project Title | Indications | Discovery | Formulation | Non-clinical | Phase I | Phase II | Phase III | NDA |
|---|---|---|---|---|---|---|---|---|---|
| Submitted Drugs (Improved New Drugs) |
DHNP-2501 | Central Nervous System |
|
||||||
| DN-2024001 | Hyperlipidemia |
|
|||||||
| DHNP-2401 | Obesity |
|
|||||||
| DHNP-2302 | Obesity |
|
|||||||
| DHNP-2301 | Gastroesophageal Reflux Disease |
|
|||||||
| DHNP-2204 | Obesity |
|
|||||||
| DHNP-2203B | Hypertension |
|
|||||||
| DHNP-2203A | Hypertension |
|
|||||||
| DHNP-2001A | Gastroesophageal Reflux Disease |
|
|||||||
| DHNP-2001B | Gastroesophageal Reflux Disease |
|
|||||||
| Generic Drugs | DN-2025001 | Analgesics |
|
||||||
| DHNP-2025 | Diabetes |
|
|||||||
| DN-2024005 | Gastroesophageal Reflux Disease |
|
|||||||
| DN-2024004 | Hepatic Disease Treatments |
|
|||||||
| DN-2024003 | Antipyretic, Analgesic, Anti-inflammatory |
|
|||||||
| DN-2024002 | Hyperlipidemia |
|
|||||||
| DHNP-2306 | Analgesics |
|
|||||||
| DHNP-2023 | Epilepsy, Obesity |
|
|||||||
| DHNP-2104 | Obesity |
|
|||||||
| DHNP-2205 | Gonadotropins |
|
|||||||
Bio Research Institute
Human Medicines

| Indication | Code | Research | Discovery | Preclinical | Phase I | Phase II | Phase III | |
|---|---|---|---|---|---|---|---|---|
| Dengue virus | DHNPB-0001 |
|
||||||
| Cancer cachexia | DHNPB-0002 |
|
||||||
| HBV | DHNPB-0003 |
|
||||||
| Subcutaneous drug delivery | DHNPB-0005 |
|
||||||
Veterinary Medicines

| Product | Indication | Code | Formulation | Non-clinical | Phase I | Phase II | Phase III | NDA | |
|---|---|---|---|---|---|---|---|---|---|
| Nustem | Herniated Disc | DHNP-D01 |
DHNP-D01
Animal Stem Cell Therapy for Spinal Cord Injury based on Heat Treatment
|
||||||
VET Lab

| Indication | Code | Formulation | Non-clinical | Phase I | Phase II | Phase III | NDA | |
|---|---|---|---|---|---|---|---|---|
| Combination Antibiotics | DHNP-L01 |
|
||||||
| Joint & Bone Treatments | DHNP-D02 |
|
||||||


Home
